The management of Hodgkin disease in the young child

Current Opinion in Pediatrics

Volumn 15, Issue 1, 2003, Pages 10-16

  Schwartz, Cindy L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE SULFATE;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CORONARY ARTERY ATHEROSCLEROSIS; DOSE RESPONSE; DRUG EFFICACY; HODGKIN DISEASE; HUMAN; HYPOPLASIA; HYPOTHYROIDISM; INFERTILITY; LEUKEMIA; LUNG TOXICITY; MOLECULAR MECHANICS; ORGAN INJURY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION FIELD; REED STERNBERG CELL; REVIEW; SECOND CANCER; SIDE EFFECT; VALVULAR HEART DISEASE;

ADOLESCENT; ADULT; AGE FACTORS; ANTINEOPLASTIC AGENTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; HODGKIN DISEASE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); TIME FACTORS;

EID: 0037305984     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200302000-00003     Document Type: Review

References (65)

1. Devita VT, Simon RM, Hubbard SM, et al.: Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980, 92:587-595.
2. Santoro N, Bonadonna G, Bonfante V, et al.: Alternative drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med 1982, 306:770-775.
3. Thomas AB, Wallace WHB: Treatment of pediatric Hodgkin's disease: a balance of risks. Eur J Cancer 2002, 38:468-477. •• This review gives the results of a number of recent trials as well as a review of the long-term toxicities of treatment.
4. Bohlen H, Kessler M, Sextro M, et al.: Poor clinical outcome of patients with Hodgkin's disease and elevated IL-10 in serum levels. Clinical significance of interleukin-10 serum levels for Hodgkin's disease. Ann Hematol 2000, 79:110-113.
5. Viviani S, Notti P, Bonfante V, et al.: Elevated pretreatment serum levels of IL-10 are associated with a poor prognosis in Hodgkin's disease, The Milan Cancer Institute experience. Med Oncol 2000, 17:59-63.
6. Sarris AH, Kliche KO, Pethambaram P, et al.: Interleukin-10 levels are often elevated in serum of adults with Hodgkin's disease and are associated with inferior failure free survival. Ann Oncol 1999, 10:433-440.
7. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998, 339:1506-1514.
8. Garrett KM, Hoffer FA, Behm FG, et al.: Interventional radiology techniques for the diagnosis of lymphoma or leukemia. Pediatr Radiol 2002, 32:653-662. • Interesting review of outcome with the use of interventional techniques. In particular, these results shed light on the reasons for considering an open biopsy procedure to secure the diagnosis of HD.
9. Karayalcin G, Behm FG, Gieser PW, et al.: Lymphocyte predominant Hodgkin disease: clinico-pathologic features and results of treatment - the Pediatric Oncology Group experience. Med Pediatr Oncol 1997, 29:519-525.
10. Mendenhall NP: The role of radiation in the management of Hodgkin's disease: an update. Cancer Invest 1999, 17:47-55.
11. Dieckmann K, Potter R, Wagner W, et al.: Up-front centralized data review and individualized treatment proposals in a multi-center pediatric Hodgkin's disease trial with 71 participating hospitals: the experience of the German-Austrian pediatric multi-center trial DAL-HD-90. Radiother Oncol 2002, 62:191-200. •• This is an important study showing the need for centralized review of imaging studies for staging and radiation planning, a factor that significantly impacts efficacy of therapy.
12. Wirth A, Corry J, Laidlaw C, et al.: Salvage radiotherapy for Hodgkin's disease following chemotherapy failure. Int J Radiat Oncol Biol Phys 1997, 39:599-607.
13. Weihrauch, MR, Re D, Scheidhauer K, et al.: Thoracic positron emission tomography using 18F-flurodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood 2001, 98:2930-2934.
14. Dittman H, Sokler M, Kollmannsberger C, et al.: Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin's lymphoma. Oncol Rep 2001, 8:1393-1399.
15. Montravers F, McNamara D, Landman-Parker, et al.: FDG in childhood lymphoma: clinical utility and impact on management. Eur J Nucl Med Mol Imaging 2002, 29:1155-1165. •• With the plethora of such studies in adults, this currently represents the only review of PET in childhood lymphoma. Positive emission tomography is a rapidly evolving modality that specifically requires validation in children.
16. Golder W: Positron emission tomography and lymphoma therapy. Onkologie 2001, 4:496-498.
17. Sandherr M, von Schilling C, Link T, et al.: Pitfalls in imaging Hodgkin's disease with computed tomography and positron emission tomography using fluorine-18-fluorodeoxyglucose. Ann Oncol 2001, 12:719-722. • Imaging studies can at times be deceiving. This study helps in the consideration of reasons that the images may not be what they seem.
18. Wolden SL, Lamborn KR, Cleary SF, et al.: Second cancers following pediatric Hodgkin's disease. J Clin Oncol 1998, 16:536-544.
19. Donaldson SS, Link MP: Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease. J Clin Oncol 1987, 5:742-749.
20. Mauch PM, Weinstein H, Botnick L, et al.: An evaluation of long-term survival and treatment complications in children with Hodgkin's disease. Cancer 1988, 51:925-932.
21. Metayer C, Lynch CF, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 2000, 18:2435-2443.
22. Bhatia S, Robison LL, Oberline O, et al.: Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996, 334:745-751.
23. Boivin JF, Hutchison GB, Lubin JH, et al.: Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992, 69:1241-1247.
24. Hancock SL, Donaldson SS, Hoppe RT: Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol 1993, 11:1208-1215.
25. Hudson MM, Poquette CA, Lee J, et al.: Increased mortality after successful treatment for Hodgkin's disease. J Clin Oncol 1998, 16:3592-3600.
26. Bokemeyer C, Schmoll HJ, van Rhee J, et al.: Long-term gonadal toxicity after therapy and non-Hodgkin's lymphoma. Ann Hematol 1994, 68:105-110.
27. Schellong G: The balance between cure and late effects in childhood Hodgkin's lymphoma: the experience of the German-Austrian Study-Gropsince 1978. German-Austrian Pediatric Hodgkin's Disease Study Group. Ann Oncol 1996, 7:67-72.
28. Bramswig JH, Heimes U, Heiermann E, et al.: The effect of different cumulative doses of chemotherapy on testicular function: results in 75 patients treated for Hodgkin's disease during childhood or adolescence. Cancer 1990, 65:1298-1302.
29. Smith M, Rubinstein L, Ungerleider R: Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatr Oncol 1994, 23:86-98.
30. Blayney DW, Longo DL, Yung RC, et al.: Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Eng J Med 1987, 316:710-714.
31. Schellong G, Riepenhausen M, Creutzig U, et al.: Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. J Clin Oncol 1997, 15:2247-2253.
32. Pratt CB, Ransom JL, Evans WE: Age-related Adriamycin cardiotoxicity in children. Cancer Treat Rep 1978, 62:1381-1385.
33. Steinherz LJ, Steinherz PG, Tan CT, et al.: Cardiac toxicity 4 to 20 years after completing anthracycline therapy, JAMA 1991, 266:1672-1677.
34. Lipshultz SE, Colan SD, Gelber RD, et al.: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991, 324:808-814.
35. Fryer CJH, Hutchinson RJ, Krailo M, et al.: Efficacy and toxicity of 12 courses of a BVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children Cancer Study Group. J Clin Oncol 1990, 8:1971-1980.
36. Weiner MA, Leventhal B, Brecher ML, et al.: Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 1997, 15:2769-2779.
37. Nachman JB, Sposto R, Herzog P, et al.: Randomized comparison on low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002, 20:3765-3771. •• The major study of children with HD in the Children's Cancer Group showing that radiation enhances event-free survival, although it is too early to know the real impact on overall survival.
38. Ruhl U, Albrecht M, Dieckmann K, et al.: Response-adapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 Trial. Int J Radiat Oncol Biol Phys 2001, 51:1209-1218. •• The major study of children with HD in Germany, in which radiation dose was determined using a response-based paradigm.
39. Sklar C, Whitton J, Mertens A, et al.: Abnormalities of the thyroid in survivors of Hodgkin's Disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metabol 2000, 85:3227-3232.
40. Schwartz CL, Tebbi C, Constine LS, et al.: Response-based therapy for pediatric Hodgkin's disease: Pediatric Oncology Group (POG) Protocols 9425/9426. Med Pediatr Oncol 2001, 37:263.
41. Donaldson SS, Hudson MM, Lamborn KR, et al.: VAMP and low-dose, involved-field radiation for children and adolescents with favorable, early-stage Hodgkin's disease: results of a prospective clinical trial. J Clin Oncol 2002, 20:3081-3087. • Outcomes for low-stage HD with treatment that does not include either alkylating agents or etoposide, but does include anthracycline and low-dose radiation.
42. Tebbi CK, Mendenhall N, Schwartz C, et al.: Response dependent treatment of stages IA, IIA, and IIIA1 micro Hodgkin's disease with DBVE and low dose involved field irradiation with or without dexrazoxane. Leuk Lymphoma 2001, 42(suppl 2):P100.
43. Landman-Parker J, Pacquement T, Habrand JL, et al.: Localized childhood Hodgkin's disease: response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 2000, 18:1500-1507.
44. Schellong G, Potter R, Bramswig J, et al.: High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999, 17:3736-3744.
45. Tebbi C, Schwartz C, London W, et al.: Hematologic effects of dexrazoxane used with DBVE regimen for treatment of early-stage Hodgkin's disease in children. Leuk Lymphoma 2001, 42(suppl 2):P083.
46. Friedman AM, Hudson NM, Weinstein JH, et al.: Treatment of unfavorable childhood Hodgkin's disease with VEPA and low-dose, involved-field radiation. J Clin Oncol 2002, 20:3088-3094.
47. Schwartz CL, Constine LS, London WB, et al.: POG 9425, response-based, intensively timed therapy for intermediate/high stage pediatric Hodgkin's disease. Proc ASCO 2002, 21:1555.
48. DeVita VT, Hubbard SM, Longo DL: Treatment of Hodgkin's disease. J Natl Cancer Inst Monogr 1990, 10:19-28.
49. Von Rijswijk JK, Haaron C, Dekke AW, et al.: Dose intensity of MOPP chemotherapy in survival in Hodgkin's disease. J Clin Oncol 1989, 7:1766-1768.
50. Carde P, MacKintosh FR, Rosenberg SA: A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy. J Clin Oncol 1983, 1:146-153.
51. Bartlett N, MacKinton FR, Rosenberg SA, et al.: Brief chemotherapy, standard and adjuvant radiotherapy for advanced stage Hodgkin's disease: a preliminary report. J Clin Oncol 1995, 13:1080.
52. Horning SJ, Hoppe RT, Breslin S, et al.: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. J Clin Oncol 2002, 20:630-637. • Description of regimen used in adults that uses dose-intensive, short-duration chemotherapy followed by radiation.
53. Diehl V, Franklin J, Hasenclever D, et al.: BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 1998, 16:3810-3821.
54. Moskowitz C, Nimer S, Zelenetz A, et al.: A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001, 97:616-623.
55. Anderson JE, Litzow MR, Appelbaum FR, et al.: Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 1993, 11:2342-2350.
56. Lazarus HM, Loberiza FR Jr, Zhang MJ, et al.: Autotransplants for Hodgkin's disease in first relapse or second remission: a report from the autologous blood and marrow transplant registry (ABMTR). Bone Marrow Transplant 2001, 27:387-396. •• Important review of a large cohort of patients (414) from the ABMT undergoing autologous blood and marrow transplant from 1989 to 1995, thus providing modern but sufficiently mature data regarding outcome and prognostic factors.
57. Kobrinsky NL, Sposto R, Shah NR, et al.: Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and L-Asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol 2001, 19:2390-2396. • A novel reinduction regimen for childhood lymphoma, with excellent outcomes for recurrent/refractory Hodgkin's disease using agents not used as part of initial therapeutic regimens.
58. Wimmer R, Weiner M, Schwartz C, et al.: A Pediatric Oncology Group Study. Cytosine arabinoside (A), cis-platinum (P), and etoposide (E) for the treatment of patients with relapsed Hodgkin's disease (HD). 5th International Conference on Malignant Lymphoma; 1993; Lugano, Switzerland.
59. Krikorian A, Breillout F: Vinorelbine (navelbine): a new semisynthetic vinca alkaloid. Onkologie 1991, 14:7-12.
60. Devizzi L, Santoro A, Bonfante V, et al.: Vinorelbine: an active drug for the management of patients with heavily pretreated Hedgkin's disease. Ann Oncol 1994, 5:817-820.
61. Santoro A, Bredenfeld H, Devizzi L, et al.: Gemcitabine in the treatment of refractory Hedgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000, 18:2615-2619.
62. Zinzani PL, Bendandi M, Stefeni V, et al.: Value of gemcitabine treatment in heavily pretreated Hedgkin's disease patients. Hematologica 2000, 85:926-929.
63. Bargou RC: High-level nuclear NF-κB and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood 1996, 87:4340-4347.
64. Yin MJ, Yamamoto Y, Gaynor RB: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa) B kinase-beta. Nature 1998, 39:15-17.
65. Adams J: Proteasome inhibition in cancer: development of PS-341. Semin Oncol 2001, 28:613-619. • Review of a new chemotherapeutic approach that may be of particular importance in the treatment of Hodgkin's disease.